Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Orient Europharma Co's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Orient Europharma Co's Dividend Payout Ratio or its related term are showing as below:
During the past 13 years, the highest Dividend Payout Ratio of Orient Europharma Co was 1.09. The lowest was 0.34. And the median was 0.71.
ROCO:4120's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 13 years, the highest Trailing Annual Dividend Yield of Orient Europharma Co was 9.09%. The lowest was 1.74%. And the median was 3.10%.
During the past 3 years, the average Dividends Per Share Growth Rate was 5.60% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Orient Europharma Co was 72.20% per year. The lowest was -22.10% per year. And the median was 2.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Orient Europharma Co (ROCO:4120) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Orient Europharma Co Dividend Payout Ratio Related Terms
Orient Europharma Co Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Orient Europharma Co's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4120 vs ZTS, UTHR: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Europharma Co Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Orient Europharma Co's Dividend Payout Ratio falls into.
Orient Europharma Co Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Orient Europharma Co's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Europharma Co (ROCO:4120) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Orient Europharma Co and its competitors. Over the past decade, Orient Europharma Co's Dividend Payout Ratio has ranged from 0.34 to 1.09. According to the industry distribution chart, Orient Europharma Co ranks #999999 out of 445 companies in the Drug Manufacturers industry.
Is Orient Europharma Co's Dividend Payout Ratio too high?
Orient Europharma Co's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 1.09. Based on the distribution chart, Orient Europharma Co ranks #999999 out of 445 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orient Europharma Co has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Europharma Co ranks #999999 out of 445 companies for Dividend Payout Ratio. This places Orient Europharma Co in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, Orient Europharma Co's own Dividend Payout Ratio has ranged from 0.34 to 1.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Orient Europharma Co and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Europharma Co's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Orient Europharma Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued.
The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98.
GuruFocus considers Orient Europharma Co to be Fairly Valued.
Key valuation signals for ROCO:4120:
Dividend Payout Ratio: 0.00
GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score
Get the complete analysis for ROCO:4120
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4120 has been successfully added to your 
